Physician profile
Sunil Skaria
NPI 1124129234
$2,096.04
in general payments reported to CMS, 2019-2025
29 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $217 · 2021: $274 · 2022: $456 · 2023: $314 · 2024: $274 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966 · Education: $19.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.29 |
| Education | $19.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $289.53 | 2019-2023 | Veltassa |
| Bard Peripheral Vascular, INC. | $264.61 | 2019-2021 | |
| Glaxosmithkline, LLC. | $192.74 | 2022-2024 | Benlysta, Jesduvroq, Nucala |
| Travere Therapeutics, INC. | $149.06 | 2023-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $147.51 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $138.44 | 2023-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.51 | 2024 | Jardiance |
| Renalytix Ai, INC. | $82.60 | 2022 | |
| Abiomed | $67.00 | 2025 | |
| Amgen INC. | $60.10 | 2021-2024 | Krystexxa |
| Horizon Therapeutics Plc | $55.51 | 2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $49.14 | 2025 | |
| Fresenius USA Marketing, INC. | $46.10 | 2022-2024 | |
| Novo Nordisk INC | $45.08 | 2024-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $43.35 | 2021-2024 | Jynarque |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $43.31 | 2022-2025 | Glassia |
| Apellis Pharmaceuticals, INC. | $36.93 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $35.00 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $31.85 | 2022 | |
| Calliditas Therapeutics US INC. | $28.70 | 2024 | |
| Daiichi Sankyo INC. | $28.30 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.14 | 2025 | Dupixent |
| Abbott Laboratories | $24.13 | 2021 | |
| Tactile Systems Technology INC | $21.67 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.91 | 2023 | Oxlumo |
| Chiesi USA, INC. | $18.80 | 2023 | Elfabrio |
| Verona Pharma, INC. | $16.96 | 2025 | Ohtuvayre |
| Genzyme Corporation | $16.04 | 2025 | |
| Akebia Therapeutics INC | $14.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Skaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.